(SANFP; Aa3/AA/NR)
Reuters reporting that "concerns raised by vaccine skeptics" will lead to "fresh scrutiny" by the FDA of RSV treatments Beyfortus and Enflonsia
Minor impact. Sanofi most exposed.
• Sanofi earns ~4.3% from Beyfortus
• Astra Zeneca earned 1% from Beyfortus 9M 25
• Merck & Co expect to make $250m from Enflonsia next year as it is still a young drug. Peak sales expected to be several hundred million. Small compared to $64bn annual revenue.
Find more articles and bullets on these widgets:
Indeed NY's Williams has already begun pointing to potential for balance sheet re-expansion to begin again, with "reserve management" purchases intended to keep Fed liabilities rising in line with market demand:


The Fed's latest H.4.1 release on Nov 5 showed reserves picked up from the prior week's post-2020 lows to $2.85T, up $24B in the latest week but still down $182B over the last month.


A few highlights from the Fed's latest Financial Stability report out today (link):